National Library of Medicine Sets July Regents Meeting
Published Date: 6/5/2026
Notice
Summary
The National Library of Medicine’s Board of Regents will hold a virtual meeting on July 16, 2026, with some parts open to the public and others closed to protect private info and trade secrets. This meeting affects researchers and grant applicants, as grant reviews will happen behind closed doors. Anyone can watch the open sessions online and send comments up to 15 days before the meeting—no registration needed!
Analyzed Economic Effects
3 provisions identified: 3 benefits, 0 costs, 0 mixed.
Grant Reviews Held Behind Closed Doors
On July 16, 2026, the Board will meet in a closed session from 12:00 p.m. to 1:00 p.m. to review and evaluate grant applications. The meeting is closed under 5 U.S.C. 552b(c)(4) and (c)(6) because discussions could disclose confidential trade secrets, commercial property, or personal information.
Open Sessions Videocast; Public Comments Allowed
Anyone can view the open parts of the virtual meeting via the NIH Videocast on July 16, 2026: 11:00 a.m.–12:00 p.m. and 1:00 p.m.–2:30 p.m., and registration is not required. Any member of the public may submit written comments no later than 15 days in advance of the meeting by sending them to the listed contact person.
Accommodations Require Advance Notice
If you need special assistance or reasonable accommodations to view the virtual meeting, you should notify the Contact Person (Sarah Edwards) in advance of the July 16, 2026 meeting. The notice requirement applies to attendees who need accommodation to access the videocast.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-15565, Proposed Collection; 60-Day Comment Request, Data Use Certification for the NIH Brain Development Cohorts (NBDC) Data Hub, (National Institute on Drug Abuse)
In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. The purpose of this revision is to update instructions for the Research Data Use Statement and the Progress Report, and to add new instructions for attesting to National Institute of Standards & Technology (NIST) security compliance, and for a Project Close-out at the time of project completion. Burden levels remain unchanged.
2026-14964, Center for Scientific Review; Notice of Closed Meeting
The Center for Scientific Review is holding a closed virtual meeting on August 19, 2026, to review neuroscience career development grant applications. This meeting is private to protect sensitive info like trade secrets and personal details. Researchers applying for these grants should note the date, as funding decisions could impact their projects and careers.
2026-14980, Government Owned Invention Available for License: Pigment Epithelium-Derived Factor Peptides and Their Use for Treating Retinal Degeneration
The National Eye Institute has a cool new invention using special peptides to help protect eyes from inherited diseases like retinitis pigmentosa, which causes vision loss for over 100,000 Americans. They’re looking for partners to help develop easy-to-use eyedrops or gene therapy to slow down or stop this eye damage. This could bring hope and new treatments to many people with few options, and interested parties can start talking to the NIH now!
2026-14966, Government-Owned Inventions; Availability for Licensing
The National Institutes of Health is offering a new Ebola vaccine invention for companies to license and develop quickly. This vaccine targets the Bundibugyo virus and promises fast and lasting protection, helping stop outbreaks in Central Africa. Businesses interested in licensing should act soon to bring this life-saving tech to market and can contact NIH for details.
2026-14981, Government Owned Invention Available for License: Nucleophosmin 1 (NPM1) Mutation-Specific T Cell Receptors for Targeted Treatment of Acute Myeloid Leukemia (AML)
The government has developed special T cell receptors that can target a tough type of blood cancer called acute myeloid leukemia (AML), especially in patients with a specific genetic marker. These new receptors promise safer, more precise treatment with fewer side effects than current options. Researchers and companies can now license this invention to help bring this exciting therapy to patients faster.
2026-14848, Prospective Grant of an Exclusive Patent License: RXFP1 AGONISTS
The National Institutes of Health plans to give Modala Bio an exclusive license to use new RXFP1 agonist inventions that could help treat diseases like cancer, heart failure, and fibrosis. This means Modala Bio gets special rights to develop and sell these promising medicines worldwide. If you want to comment or apply for a license, you have until August 24, 2026, so don’t miss out!
Previous / Next Documents
Previous: 2026-11356, Forged Steel Fittings From India and South Korea; Scheduling of Full Five-Year Reviews
The U.S. International Trade Commission is reviewing whether to keep or end special taxes on forged steel fittings from India and South Korea. This review affects businesses that import or use these steel parts and could impact prices or trade rules soon. The Commission may take up to 90 extra days to decide, so stay tuned for updates!
Next: 2026-11359, Agency Information Collection Activities; Revision of a Currently Approved Collection: Medical Certification for Disability Exceptions
USCIS is updating the form used to certify medical disabilities for immigration exceptions. This affects applicants needing special medical consideration and asks for public feedback by July 6, 2026. The update aims to keep the process clear and efficient without adding extra costs or delays.